Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis

References

• 1. China Cardiovascular Health and Disease Report Writing Group. Summary of the China Cardiovascular Health and Disease Report 2020. Chin. Circ. J. 36(06), 521–545 (2021).
  Google Scholar
• 2. Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 290, 140–205 (2019).
  MedlineGoogle Scholar
• 3. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
  Medline CASGoogle Scholar
• 4. Junren Z, Runlin G, Shuiping Z. Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China (2016 Revised Edition). Chin. Circ. J. 31(10), 937–953 (2016).
  Google Scholar
• 5. Donnelly LA, Palmer CN, Whitley AL. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet. Genomics 18(4), 279–287 (2008).
  Medline CASGoogle Scholar
• 6. Pasanen MK, Miettinen TA, Gylling H. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet. Genomics 18(10), 921–926 (2008).
  Medline CASGoogle Scholar
• 7. Hu L, Shuiping Z. Apolipoprotein E and cholesteryl ester transporter protein gene polymorphisms in relation to coronary heart disease. Clin. Focus 24(24), 2127–2130 (2009).
  Google Scholar
• 8. Saxena R, Voight BF, Lyssenko V. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316(5829), 1331–1336 (2007).
  Medline CASGoogle Scholar
• 9. Utermann G. Apolipoprotein E polymorphism in health and disease. Am. Heart J. 113(2 Pt 2), 433–440 (1987).
  Medline CASGoogle Scholar
• 10. Link E, Parish S, Armitage J. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
  Medline CASGoogle Scholar
• 11. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80(4), 356–366 (2006).
  Medline CASGoogle Scholar
• 12. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7), 787–802 (2007).
  CASGoogle Scholar
• 13. Meyer ZSH, Albers M, Baumeister SE. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet. Genomics 25(1), 8–18 (2015).
  MedlineGoogle Scholar
• 14. Couvert P, Giral P, Dejager S. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9(9), 1217–1227 (2008).
  CASGoogle Scholar
• 15. Tong Y. Advances in the pharmacogenomics of fluvastatin. Drug Eval. 17(21), 3–5 (2020).
  Google Scholar
• 16. Xiang Q, Wu W, Zhao N. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian J. Pharm. Sci. 15(2), 264–272 (2020).
  MedlineGoogle Scholar
• 17. Zhou Q, Ruan ZR, Yuan H. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. Arzneimittelforschung 62(11), 519–524 (2012).
  Medline CASGoogle Scholar
• 18. Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151(4), 264–269 (2009).
  MedlineGoogle Scholar
• 19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002).
  MedlineGoogle Scholar
• 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177–188 (1986).
  Medline CASGoogle Scholar
• 21. Zuccaro P, Mombelli G, Calabresi L. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 55(4), 310–317 (2007).
  Medline CASGoogle Scholar
• 22. Kirchheiner J, Kudlicz D, Meisel C. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74(2), 186–194 (2003).
  Medline CASGoogle Scholar
• 23. Ballantyne CM, Herd JA, Stein EA. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol. 36(5), 1572–1578 (2000).
  Medline CASGoogle Scholar
• 24. Weining L, Yong X, Anping X. Association of apolipoprotein E gene polymorphisms with lipid-lowering efficacy of fluvastatin. Lab. Med. Clin. 8(18), 2181–2182 (2011).
  Google Scholar
• 25. Dergunov AD, Perova NV, Visvikis S. Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vascul. Pharmacol. 40(5), 237–245 (2003).
  Medline CASGoogle Scholar
• 26. Buzková H, Pechandová K, Danzig V. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med. Sci. Monit. 18(8), R512–R517 (2012).
  Google Scholar
• 27. Li ZQ, Li CY, Wan X. Effect of CYP2C9*3 gene polymorphism on lipid-lowering efficacy of fluvastatin in a Chinese hyperlipidemic population. Trop. J. Pharm. Res. 16(9), 2261–2265 (2017).
  CASGoogle Scholar
• 28. Cooper-DeHoff RM, Niemi M, Ramsey LB. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin. Pharmacol. Ther. 111(5), 1007–1021 (2022).
  Medline CASGoogle Scholar